Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
24.21
-0.95 (-3.78%)
At close: Nov 6, 2026, 4:00 PM EST
24.29
+0.08 (0.33%)
Pre-market: Nov 9, 2026, 4:15 AM EST
Collegium Pharmaceutical Revenue
Collegium Pharmaceutical had revenue of $216.34M in the quarter ending September 30, 2026, with 3.33% growth. This brings the company's total for the last twelve months to $815.19M, up 7.68% year-over-year. In the year 2025, Collegium Pharmaceutical had annual revenue of $780.57M with 23.62% growth. That makes Collegium Pharmaceutical the 8,629th largest company in the world by revenue and 1,937th in the United States.
Revenue (ttm)
$815.19M
Revenue Growth
+7.68%
P/S Ratio
0.92
Revenue / Employee
$1,927,154
Employees
423
Market Cap
752.34M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 780.57M | 149.12M | 23.62% |
| Dec 31, 2024 | 631.45M | 64.68M | 11.41% |
| Dec 31, 2023 | 566.77M | 102.83M | 22.17% |
| Dec 31, 2022 | 463.93M | 187.07M | 67.56% |
| Dec 31, 2021 | 276.87M | -33.15M | -10.69% |
| Dec 31, 2020 | 310.02M | 13.32M | 4.49% |
| Dec 31, 2019 | 296.70M | 16.29M | 5.81% |
| Dec 31, 2018 | 280.41M | 251.94M | 884.73% |
| Dec 31, 2017 | 28.48M | 26.77M | 1,564.29% |
| Dec 31, 2016 | 1.71M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Phibro Animal Health | 1.54B |
| Tilray Brands | 963.10M |
| Evotec SE | 815.72M |
| Amphastar Pharmaceuticals | 745.79M |
| Ironwood Pharmaceuticals | 400.30M |
| Evolus | 325.47M |
| Harrow | 275.59M |
| Cronos Group | 206.20M |
COLL News
- 2 days ago - Collegium Pharmaceutical price target lowered to $28 from $43 at Piper Sandler - TheFly
- 3 days ago - Collegium Pharmaceutical announces $50M accelerated share repurchase program - TheFly
- 3 days ago - Collegium Pharmaceutical reports Q3 EPS $1.96, consensus $1.86 - TheFly
- 3 days ago - Collegium Pharmaceutical Earnings Call Transcript: Q3 2026 - Transcripts
- 3 days ago - Collegium Pharmaceutical Earnings release: Q3 2026 - Filings
- 3 days ago - Collegium Pharmaceutical Quarterly report: Q3 2026 - Filings
- 3 days ago - Collegium Pharmaceutical Slides: Q3 2026 - Filings
- 3 days ago - Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance - GlobeNewsWire